These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38934177)

  • 1. 8th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities in 2024.
    Nephron; 2024; 148 Suppl 1():1-76. PubMed ID: 38934177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fabry disease].
    Subran B; Montagner C; London J; Lidove O; Mauhin W
    Rev Prat; 2020 May; 70(5):537-540. PubMed ID: 33058644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Foreword. The 8th Annual European Round Table on Fabry Disease.
    Wanner C; Ramaswami U
    Clin Ther; 2008; 30 Suppl B():S39. PubMed ID: 18395132
    [No Abstract]   [Full Text] [Related]  

  • 5. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
    Frustaci A; Russo MA; Chimenti C
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
    [No Abstract]   [Full Text] [Related]  

  • 6. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
    García de Lorenzo A;
    Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
    Hughes DA; Nicholls K; Sunder-Plassmann G; Jovanovic A; Feldt-Rasmussen U; Schiffmann R; Giugliani R; Jain V; Viereck C; Castelli JP; Skuban N; Barth JA; Bichet DG
    Am J Med Genet A; 2019 Jun; 179(6):1069-1073. PubMed ID: 30920142
    [No Abstract]   [Full Text] [Related]  

  • 8. Fabry disease cardiomyopathy: from genes to clinical manifestations.
    Kertész AB; Édes I
    Curr Pharm Biotechnol; 2012 Oct; 13(13):2477-84. PubMed ID: 22280422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Changing Landscape of Fabry Disease.
    Svarstad E; Marti HP
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
    [No Abstract]   [Full Text] [Related]  

  • 10. [Priapism: a severe paediatric complication of Fabry disease].
    Labarthe F; de Bodman C; Maruani A; Szwarc C; Froissart R; Lorette G; Lardy H
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S217-9. PubMed ID: 21211667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
    Waldek S; Feriozzi S
    BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anderson-Fabry disease: developments in diagnosis and treatment.
    Mehta AB
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching for an additional treatment to slowing the progression of Fabry disease.
    Ravarotto V; Carraro G; Simioni F; Bertoldi G; Pagnin E; Calò LA
    Minerva Med; 2019 Apr; 110(2):176-178. PubMed ID: 30821433
    [No Abstract]   [Full Text] [Related]  

  • 15. Fabry disease previously diagnosed as Henoch-Schonlein purpura.
    Kim JH; Han DH; Park MY; Choi SJ; Kim JK; Hwang SD; Jin SY
    Korean J Intern Med; 2015 Nov; 30(6):925-7. PubMed ID: 26552470
    [No Abstract]   [Full Text] [Related]  

  • 16. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.
    Roganović J
    Pediatr Dermatol; 2011; 28(6):727-728. PubMed ID: 22082470
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Schiffmann R; Hughes DA; Linthorst GE; Ortiz A; Svarstad E; Warnock DG; West ML; Wanner C;
    Kidney Int; 2017 Feb; 91(2):284-293. PubMed ID: 27998644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease: a rare disorder calling for personalized medicine.
    Lerario S; Monti L; Ambrosetti I; Luglio A; Pietra A; Aiello V; Montanari F; Bellasi A; Zaza G; Galante A; Salera D; Capelli I; La Manna G; Provenzano M
    Int Urol Nephrol; 2024 Oct; 56(10):3161-3172. PubMed ID: 38613662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.